TransGenic Group

TransGenic Group OCF Margin

The Operating Cash Flow Margin of TransGenic Group (2342.T) as of Nov 11, 2026 is 0.20 %. In the previous year, Operating Cash Flow Margin was 0.72 % — a change of -72.82% (lower).

OCF Margin

0.20 %

YoY

-72.82%

Last updated:

Operating Cash Flow Margin of TransGenic Group is 2026 0.20 % . Operating Cash Flow Margin of TransGenic Group was 2025 0.72 % . It decreases by -72.82% lower compared to the previous year.

The TransGenic Group OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2019
1.70 JPY
Jan 1, 2020
-0.19 JPY
Jan 1, 2021
11.07 JPY
Jan 1, 2022
14.23 JPY
Jan 1, 2023
-12.51 JPY
Jan 1, 2024
-3.00 JPY
Jan 1, 2025
0.72 JPY
Jan 1, 2026
0.20 JPY
The TransGenic Group OCF Margin history
YEAROCF MarginYoY
0.20 %-72.82%
0.72 %-124.12%
-3.00 %-76.03%
-12.51 %-187.95%
14.23 %+28.56%
11.07 %-5,924.39%
-0.19 %-111.16%
1.70 %-72.01%
6.08 %-39.83%
10.11 %+8.01%
9.36 %+81.07%
5.17 %-159.09%
-8.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

Operating Cash Flow Margin of TransGenic Group is 0.20 % in 2026.

Operating Cash Flow Margin of TransGenic Group changed from 0.72 % to 0.20 %, representing a -72.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's TransGenic Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — TransGenic Group

All Key Metrics — TransGenic Group